What Is The Growth Rate Of Dolby Dlb Stock Price At 61.79 Up 1.76 20260402 ARMP Armata Pharmaceuticals Inc falls 564 as drastically wider than expected Q4 2025 net loss spooks investors CLBT Cellebrite DI Ltd Ordinary Shares narrowly tops Q4 2025 EPS estimates shares rise 37 percent on upbeat investor sentiment HIO Western reports quarterly results amid highyield market volatility fund maintains income focus DLPN Dolphin Entertainment Inc posts narrower Q3 2025 loss and 97 percent year over year revenue growth shares rise 204 percent Oil Prices Decline as USIran Talks Show Progress but Key Disagreements Persist World Insurance Expands Midwest Footprint with Kansas Agency Acquisition Amazon Faces Allegations Over Millions in Profits from NowIllegal Pricing Policy Jamie Dimon Signals JPMorgan Chase Could Pursue 20 Billion Acquisition Acknowledges Regulatory Hurdles FPIs Raise Concerns Over Rupee Depreciation and Shrinking Returns at Hong Kong Conference South Koreas Deputy PM Stresses AI Wealth Must Benefit Public Amid Samsung Labor Disputes NWSA Q1 2026 Earnings EPS Beat by 1206 on Strong Operating Performance PCVX Q1 2026 Earnings Missed Estimates Amid PreRevenue Stage Stock Inches Higher AMT Q1 2026 Earnings Strong EPS Beat Drives Positive Stock Reaction TEVA Q1 2026 Earnings EPS Beats Estimates by 878 as Generic Drugmaker Posts Strong Quarter Syprus Solutions Inc SYPR Q3 2025 Earnings Modest Profitability Amidst Operational Challenges AG Q1 2026 Earnings Silver Miner Misses EPS Estimates as Costs Weigh on Profitability Piedmont Realty Trust PDM Holds Near Support After Modest Gain SuperX AI Surges 119 Is Momentum Building for SUPX Stock Equinor ASA EQNR Faces Selling Pressure Testing Key Support Levels Blackrock Enhanced International Dividend Trust BGY Edges Higher Amid Steady Trading Ocugen Inc OCGN Holds Steady at 134 Amid Consolidation Key Levels in Focus Indian Equities and Rupee Edge Higher on RBI Support but Caution Prevails Amid Foreign Outflows FORTY Q1 2025 Earnings Reporting EPS of 123 Amid Stock Pullback KalVista Pharmaceuticals KALV Holds Steady Near Resistance as Investors Eye Key Catalysts